The Dixie Group (DXYN) Q4 2024 earnings summary

Executive summary

• Net sales for Q4 2024 were $64.4 million, down from $66.7 million in Q4 2023; full-year 2024 net sales were $265 million, a 4.1% decrease year-over-year.

• Net loss for Q4 2024 was $7.2 million versus $3.2 million in Q4 2023, which included an $8.2 million asset sale gain; full-year 2024 net loss was $13 million, or $0.88 per diluted share, compared to $2.7 million, or $0.18 per share, in 2023.

• Cost-cutting initiatives reduced selling and administrative expenses by $4.3 million in 2024; further cost reductions of over $10 million are planned for 2025.

• Inventory was reduced by $9.3 million in 2024, with a total reduction of $16 million over two years.

• Sales declines attributed to industry slowdown from high interest rates and reduced consumer confidence.

Financial highlights

• Gross profit margin declined to 24.7% of net sales in 2024 from 26.7% in 2023, impacted by lower sales volume, high utility charges, medical plan expenses, and inventory write-downs.

• Interest expense decreased to $6.4 million in 2024 from $7.2 million in 2023 due to lower rates.

• Net property, plant, and equipment increased by $2.4 million, mainly due to investments in extrusion operations.

• Year-end receivables were $23.3 million, down 1.5% year-over-year; net inventory at year-end was $66.9 million.

• Capital expenditures were $2.1 million in 2024, up from $1.0 million in 2023.

Outlook and guidance

• Cost-reduction plan for 2025 exceeds $10 million, with most actions already implemented.

• Management expects a generally flat year but anticipates improved EBITDA due to non-recurring 2024 charges and cost savings.

• Ongoing inventory reduction efforts are expected to continue generating cash flow.

• Early 2025 sales trends mirror 2024: high-end soft surface sales up, overall soft surfaces flat, hard surfaces down.

• Measures in place to reduce medical and utility costs, and further sample and sourcing cost reductions expected.